Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Themes AI

The Future of Longevity: AI and Nanorobots to Radically Extend Life

by Team Lumida
June 25, 2024
in AI, Health and Longevity
Reading Time: 3 mins read
A A
0
person holding black and white microscope

Photo by Jaron Nix on Unsplash

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways:

  1. AI-driven drug discovery could drastically cut down clinical trial times.
  2. Medical nanorobots may revolutionize immune systems by the 2030s.
  3. By 2040s, mind-backup systems might allow near-immortality.

What Happened?

Futurist Ray Kurzweil claims that AI will revolutionize drug discovery and medical interventions by the end of the 2020s. He believes biological simulators will soon generate crucial safety and efficacy data in hours, not years.

This shift could lead to faster drug approvals and save countless lives. Kurzweil also predicts that medical nanorobots will emerge in the 2030s, vastly enhancing our immune systems and treating metabolic diseases. By 2040s, he envisions mind-backup systems that could essentially render death obsolete.

Why It Matters?

These advancements could disrupt traditional medical models and extend human lifespans dramatically. Faster drug approvals would mean quicker access to lifesaving treatments. Medical nanorobots could address diseases that our natural immune systems can’t, such as cancer and neurodegenerative disorders.

The potential to back up our minds might lead to radical life extension, fundamentally changing the concept of mortality. Investors should note the profound implications for the healthcare and biotech sectors, which could experience exponential growth.

What’s Next?

Expect increased investment in AI-driven pharmaceutical research and biotech firms focused on nanotechnology. Regulatory landscapes will evolve to accommodate simulated trials, despite potential bureaucratic resistance. By the mid-2040s, mind-backup technologies will likely face ethical and security challenges, but Kurzweil is optimistic about overcoming these hurdles.

As these technologies become mainstream, they will likely follow the trajectory of the cell phone—starting expensive and exclusive, but eventually becoming widely accessible.

Source: Fortune Well
Tags: AI-driven drug discoverymedical nanorobotsmind-backup systemsRay Kurzweil
Previous Post

Bitcoin Crashes to $62K: What’s Behind the $150M Liquidation?

Next Post

TikTok Ban Could Dent Oracle’s Earnings: What Investors Need to Know

Recommended For You

OpenAI and Anthropic Are Sounding the Alarm on Chinese AI — But the White House Is Divided on What to Do

by Team Lumida
4 hours ago
OpenAI Hack: Why AI Companies Are Prime Targets for Cyberattacks

Executives at OpenAI and Anthropic are warning that powerful, cheap Chinese AI models pose dystopian risks and unacceptable security vulnerabilities, calling for regulatory restrictions — but the White...

Read more

TSMC Is Raising Chip Prices Up to 10% in 2027 — Every AI Chip Customer from Nvidia to Apple Will Pay More

by Team Lumida
4 hours ago
AI Investment Boom: How Tech Giants Are Leading the Charge

TSMC has finalized price increases of 5-10% with clients for 2027, covering both advanced and mature semiconductors, driven by rising materials, equipment, and power costs and the mounting...

Read more

The Market Misread Kimi K3 the Same Way It Misread DeepSeek — Here’s What the Semiconductor Selloff Got Wrong

by Team Lumida
1 day ago
A person holding a cell phone in their hand

Bloomberg analysis argues that Moonshot AI's Kimi K3 — which triggered a sharp semiconductor selloff similar to DeepSeek's debut — is fundamentally different from DeepSeek in one critical...

Read more

Whoop Enters Clinical Care With Joint Replacement Recovery Pilot — Can Wearable Biometrics Reduce Opioids and Speed Recovery?

by Team Lumida
1 day ago
a close up of a human skull on a black background

Whoop and surgical software company Kinomatic have launched a 12-week pilot program called Restore across three California orthopedic clinics to test whether continuous biometric monitoring — heart rate...

Read more

Xi Endorses Open-Source AI at Shanghai Conference, Casting China as Champion of Openness Against US Chip and Model Restrictions

by Team Lumida
4 days ago
China’s Bold Economic Moves: What You Need to Know Now

Chinese President Xi Jinping endorsed open-source AI development at the World AI Conference in Shanghai, framing China as a champion of openness and equality — an implicit critique...

Read more

AI Executives Are Facing Real-World Violence — Altman’s Home Firebombed, Anthropic Lobby Breached as Tech Backlash Turns Physical

by Team Lumida
5 days ago
AI Investment Boom: How Tech Giants Are Leading the Charge

Violent threats against AI companies are escalating from online abuse into real-world security incidents: an attempted firebombing of OpenAI CEO Sam Altman's home was captured on surveillance video...

Read more

Anthropic Targets October IPO — $965 Billion Valuation Would Make It the Largest Tech Debut Since the AI Era Began

by Team Lumida
5 days ago
Pentagon–Anthropic Feud Escalates as AI Policy Clash Threatens Defense Contracts

Anthropic PBC is scheduling investor meetings with banks Morgan Stanley, Goldman Sachs, and JPMorgan ahead of a potential IPO as soon as October 2026 — which would put...

Read more

$399 Signal Ring Claims to Replace the Blood Pressure Cuff — No Calibration, No Subscription, Clinical Trial at Stanford

by Team Lumida
5 days ago
Fingers hold a black smart ring with circuits visible.

Vital Signals, a three-year-old startup, has launched a $399 Signal Ring that claims to track blood pressure as accurately as a traditional arm cuff — without requiring any...

Read more

AI Chips as Diplomatic Currency: UAE Gets Expanded Nvidia Access in Exchange for Carrying Out Dozens of Iran Airstrikes

by Team Lumida
6 days ago
China’s AI Startups Challenge Global Leaders Amid U.S. Trade Curbs

The UAE gained expanded US access to advanced AI chips after aiding America in the Iran war — conducting dozens of airstrikes on Iranian targets, intercepting hundreds of...

Read more

Novo’s Obesity Pill Commands 89% Market Share — Lilly’s Foundayo Captures Just 11% After Three Months on Market

by Team Lumida
6 days ago
Novo’s Obesity Pill Commands 89% Market Share — Lilly’s Foundayo Captures Just 11% After Three Months on Market

Novo Nordisk's Wegovy pill has seized 89% of new oral obesity pill prescriptions since its January 2026 launch, leaving Eli Lilly's Foundayo — launched in April — with...

Read more
Next Post
a red cube with white text

TikTok Ban Could Dent Oracle's Earnings: What Investors Need to Know

a person holding a phone

AI and Crypto Shakeup: Nvidia and Bitcoin's Massive Drops Explained

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

red and blue light streaks

Treasury Yields Near Turning Point: Is Now the Time to Invest?

June 20, 2024
Market Watch: Fed Holds Rates, Hints at September Cut”

Are Markets Nervous? Stock Futures Decline Ahead of Key Jobs Data

September 2, 2024
Inflation Eases: Will Powell Signal Rate Cuts Soon?

Fed Rate-Cut Debate Nears End: What Traders Are Betting On

September 18, 2024

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto data centers Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Intel Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018